Drug intelligence / Profile preview

ambroxol hydrochloride + guaifenesin + levosalbutamol sulphate

Development stage
Unknown
Lead developer
Kriam Pharma
Modality
Small Molecules
Administration
Oral
01

Overview

Ambroxol hydrochloride + guaifenesin + levosalbutamol sulphate is an oral combination therapy developed by Kriam Pharma for the symptomatic treatment of productive cough and airway congestion. This formulation combines three active ingredients with complementary mechanisms: levosalbutamol, a selective beta-2 adrenergic agonist that induces bronchodilation by relaxing airway smooth muscle; ambroxol, a mucolytic agent that thins and breaks down phlegm; and guaifenesin, an expectorant that increases the volume of airway secretions to facilitate their removal. Together, these components alleviate bronchospasm and improve mucus clearance in patients with respiratory conditions such as bronchitis, bronchial asthma, and chronic obstructive pulmonary disease (COPD).

Brand names
Amvoryl LSAmvoryl LS DropAmvoryl LS Junior
Other names
Ambroxol Hydrochloride, Guaifenesin, Levosalbutamol Sulphate
02

Targets

SCN1A (Voltage-gated sodium channel protein type 1 subunit alpha)SCN10A (Sodium channel protein type X alpha subunit)ADRB2 (β2)

Beyond the preview

Go deeper on ambroxol hydrochloride + guaifenesin + levosalbutamol sulphate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ambroxol hydrochloride + guaifenesin + levosalbutamol sulphate.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call